4,901 trials
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Healthy
Primary: Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) — 13.81; 12.17; 13.63; 11.42 Millimeters of mercury (mmHg)
Cystic Fibrosis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAE) Over the Treatment Period in Part 1 and Part 2 — 37.5; 62.5; 87.5; 100.0 Percentage of…
Migraine
Primary: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) — 261; 294; 220 nanograms per milliliter (ng/mL)
Asthma
Primary: Absolute Change From Baseline in Maximum Forced Expiratory Volume Within 1 Second (FEV1) Reduction Following Bolus Methacholine Challenge in Part 1 — 0.018; 0.390…
Malaria
Primary: OZ439 Fpo — 35 Absolute bioavailability in %
Healthy Volunteers
Primary: Latency to Sleep Onset on Maintenance of Wakefulness Test (MWT) at 2 Hours Post-infusion Start — 15.68; 35.74; 40.02; 35.57 minute — p=<0.001
Neurocysticercosis
Primary: Number of Subjects Reporting Adverse Events Related to Oxfendazole Within 14 Days of Receipt of a Single Oral Dose. — 0; 0; 1; 0 Participants
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Metformin — 1109; 1087 Nano-gram per milliliter (ng/mL)
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t) — 27870.56; 30051.25 Nanogram…
Sarcoma, Soft Tissue
Primary: Pharmacokinetics (PK): Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) Doxorubicin — 2580; 2570; 2400; 2470 nanogram*hour/milliliter (ng*h/mL)
Acute Otitis Media
Primary: Number of Participants With Adverse Events — 2; 6 Participants
Autoimmune Hepatitis
Primary: Safety/Tolerability Measured by Clinical Laboratory Tests, Metabolics, Cytokines, Anti-PIF Antibody, Periodic Physical Examination, Including Vital Signs Measurements…
Healthy
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE) — 69.2; 83.3; 100.0; 66.7 percentage of participants
Influenza
Primary: Viral Shedding — 8; 4; 7; 4 Participants